VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced that it has entered into an agreement with Royal DSM N.V. (Euronext:DSM) to evaluate the application of Zymeworks’ predictive protein engineering tools in the context of discovering promising new enzymes for use in DSM’s biocatalytical processes. The results of the program may lead to future joint development activities between Zymeworks and DSM on the same or other topics and biocatalytical reactions.
